Delcath Systems to Hold Investor Update on Focus Trial Data and Future Development Plans on December 2, 2021

NEXT STORY
Cyclacel Announces Dosing of First Patient in Phase 1/2 Study of Oral Fadraciclib in Patients With Leukemias or Myelodysplastic Syndromes
PREV STORY
Wegovy™ demonstrated significant and sustained weight loss in two-year study in adults with obesity
Subscribe now to PM360
Get in touch with PM360 Experts On Call

Experts on Call

Ads

You May Also Like

Roche’s Evrysdi continues to improve motor function and survival in babies with Type 1 Spinal Muscular Atrophy (SMA)

author_avatar
NASDAQ Market News

Rheumatology Leaders Applaud Updates to Evaluation and Management Codes in CMS 2020 Physician Fee Schedule Proposed Rule

author_avatar
NASDAQ Market News

Joint Communiqué: BioNTech Evaluates mRNA Vaccine Manufacturing Solutions in Rwanda and Senegal to Improve Long-Term Vaccine Supply

author_avatar
NASDAQ Market News